Zobrazeno 1 - 10
of 5 250
pro vyhledávání: '"Sacubitril"'
Autor:
Ludek Pavlu, Marek Vicha, Jakub Flasik, Jana Petrkova, Milos Taborsky, Tereza Kacirkova, Ondrej Holy
Publikováno v:
Biomedical Papers, Vol 168, Iss 3, Pp 229-234 (2024)
Background and Aims. There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-
Externí odkaz:
https://doaj.org/article/d1f2b307edac453b86230ed6b0e4aba6
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Autor:
Antoine Garnier-Crussard
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-5 (2024)
Abstract Since 2014, sacubitril/valsartan (Entresto®) is widely prescribed for heart failure. Despite neprilysin inhibition’s benefits in heart failure, concerns about potential amyloid-beta (Aβ) accumulation and Alzheimer’s disease (AD) risk h
Externí odkaz:
https://doaj.org/article/76644807e1c6445890827294846cbe19
Autor:
Dong‐Yi Chen, Chun‐Chi Chen, Cheng‐Hung Lee, Chi‐Nan Tseng, Shao‐Wei Chen, Shang‐Hung Chang, Tien‐Hsing Chen, Pao‐Hsien Chu, I‐Chang Hsieh, Ming‐Shien Wen, Ming‐Lung Tsai, Ming‐Jer Hsieh
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 2259-2271 (2024)
Abstract Aims The PIONEER‐HF and PARAGLIDE‐HF trials aimed to determine the efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients hospitalized for AHF. However, whether the inclusion and exclusion criteria of the
Externí odkaz:
https://doaj.org/article/3df3cbf84add40b389c311b6a71fb639
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract We assessed the real-world effectiveness of sacubitril/valsartan in patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF) with an emphasis on those with older age (≥ 75 years) or with New York Heart Association (NY
Externí odkaz:
https://doaj.org/article/39c891947987435196a70a0075c976ec
Autor:
Henan Liu, Yongkang Su, Jian Shen, Yang Jiao, Ying Li, Bing Liu, Xiaoling Hou, Qinhua Jin, Yundai Chen, Zhijun Sun, Qing Xi, Bin Feng, Zhenhong Fu
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 937-949 (2024)
Abstract Aims This study sought to assess the effect of treatment of sacubitril/valsartan (S/V) on improving cardiac function and reversing cardiac remodelling in patients with acute coronary syndrome (ACS) complicated with heart failure with reduced
Externí odkaz:
https://doaj.org/article/9146933afc0c457aa179005906976ac2
Autor:
Aleix Olivella, Luis Almenar‐Bonet, Pedro Moliner, Emmanuel Coloma, Antoni Martínez‐Rubio, Marco Paz Bermejo, Ramon Boixeda, German Cediel, Ana Belén Méndez Fernández, Lorenzo Facila Rubio
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 628-636 (2024)
Abstract Worsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be imp
Externí odkaz:
https://doaj.org/article/fd3fc4ba948d4bd3b9b3019a4111c49a
Autor:
Yiwen Wang, Xuna Liu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
PurposeSacubitril/valsartan is extensively used in heart failure; however, there are few long-term safety studies of it in a wide range of populations. The aim of this study was to evaluate sacubitril/valsartan-induced adverse events (AEs) through da
Externí odkaz:
https://doaj.org/article/a6ca70cb63cd47ac9a3303f32c58c19c
Autor:
Bartosz Sadłowski, Paula Bieganek, Stanisław Łukaszewicz, Piotr Pawłowski, Julia Rybak, Jakub Kordialik, Julia Koćwin, Sandra Sarnacka, Michał Tokarski, Angelika Banasiak
Publikováno v:
Quality in Sport, Vol 17 (2024)
Introduction and purpose: Heart failure is one of the most common cardiovascular diseases worldwide. It is an important factor leading to a reduced, health-related quality of life (HRQoL) not only because of its various symptoms but also due to loss
Externí odkaz:
https://doaj.org/article/2666ee93de4f46dba54f2a54d466fe9b
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveTo detect muscular system adverse reaction signals of sacubitril/valsartan treatment combined with statins (atorvastatin, rosuvastatin, simvastatin) to provide a reference for clinical administration.MethodsMultiplicative and additive models
Externí odkaz:
https://doaj.org/article/fba579fe1b6b42f3b0e001fcfe551c29